title: Adeno-associated viral gene delivery in neurodegenerative disease.
abstract: The advent of viral gene therapy technology has contributed greatly to the study of a variety of medical conditions, and there is increasing promise for clinical translation of gene therapy into human treatments. Adeno-associated viral (AAV) vectors provide one of the more promising approaches to gene delivery, and have been used extensively over the last 20 years. Derived from nonpathogenic parvoviruses, these vectors allow for stable and robust expression of desired transgenes in vitro and in vivo. AAV vectors efficiently and stably transduce neurons, with some strains targeting neurons exclusively in the brain. Thus, AAV vectors are particularly useful for neurodegenerative diseases, which have led to numerous preclinical studies and several human trials of gene therapy in patients with Parkinson's disease, Alzheimer's disease, and pediatric neurogenetic disorders. Here, we describe an efficient and reliable method for the production and purification of AAV serotype 2 vectors for both in vitro and in vivo applications.
authors.affiliation: Laboratory of Molecular Neurosurgery, Department of Neurological Surgery, Weill Cornell Medical College, New York, NY, USA.
authors.forename: Peter F
authors.initials: PF
authors.lastname: Morgenstern
authors.forename: Roberta
authors.initials: R
authors.lastname: Marongiu
authors.forename: Sergei A
authors.initials: SA
authors.lastname: Musatov
authors.forename: Michael G
authors.initials: MG
authors.lastname: Kaplitt
mesh_terms: D000818:Animals; D000229:Dependovirus / Q000235:genetics*; D005260:Female; D020868:Gene Silencing; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D051379:Mice; D019636:Neurodegenerative Diseases / Q000235:genetics* / Q000628:therapy; D009474:Neurons / Q000378:metabolism; D016133:Polymerase Chain Reaction; D051381:Rats; D014162:Transfection / Q000379:methods*